Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Quarterly report · Q2

4886.TEDINET S100S71T
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥31.6bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥60.5bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥30.2bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥3.1bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥2.9bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥3.1bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥5.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.0bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥5.4bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥3.0bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥4.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥4.1bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥2.3bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥91.9bnat 2023-09-30Cons.Assets
Total assets¥87.1bnat 2023-03-31Cons.Assets
Total assets¥86.2bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥33.3bnat 2023-09-30Cons.Liabilities
Total liabilities¥32.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥58.6bnat 2023-09-30Cons.Net assets
Net assets / equity¥54.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥52.0bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥17.4bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥14.5bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥19.4bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥17.5bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥17.2bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥17.1bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥3.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥3.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥1.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥199m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥2.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥1.8bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥145.932023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥95.412023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥150.082022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥83.182022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥36.252022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio63.8%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio60.3%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥108m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥80m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥27m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30−¥61m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥27m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥27m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥585m
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥3.2bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥3.2bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥44m
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥28.4bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥28.4bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥31.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥31.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥27m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥3.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥114m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥86m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥28m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30−¥20m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥28m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥28m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥473m
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥3.2bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥3.2bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥231m
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥26.9bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥26.9bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥30.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥30.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥28m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥3.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 457
ItemContextValueUnit
Capital surplusPrior1YearInstant1847000000JPY
Capital surplusCurrentQuarterInstant1848000000JPY
Retained earningsPrior1YearInstant49619000000JPY
Retained earningsCurrentQuarterInstant53522000000JPY
Treasury stockPrior1YearInstant-3350000000JPY
Treasury stockCurrentQuarterInstant-3287000000JPY
Shareholders equityPrior1YearInstant49315000000JPY
Shareholders equityCurrentQuarterInstant53281000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant4590000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant4455000000JPY
Foreign currency translation adjustmentPrior1YearInstant405000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant677000000JPY
Remeasurements of defined benefit plansPrior1YearInstant222000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant206000000JPY
Valuation and translation adjustmentsPrior1YearInstant5218000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant5339000000JPY
Net assetsPrior1YearInstant54533000000JPY
Net assetsCurrentQuarterInstant58621000000JPY
Liabilities and net assetsPrior1YearInstant87138000000JPY
Liabilities and net assetsCurrentQuarterInstant91920000000JPY
Net salesPrior1YTDDuration30172000000JPY
Net salesCurrentYTDDuration31648000000JPY
Cost of salesPrior1YTDDuration15870000000JPY
Cost of salesCurrentYTDDuration16461000000JPY
Gross profitPrior1YTDDuration14301000000JPY
Gross profitCurrentYTDDuration15186000000JPY
Selling general and administrative expensesPrior1YTDDuration11422000000JPY
Selling general and administrative expensesCurrentYTDDuration12130000000JPY
Operating incomePrior1YTDDuration2879000000JPY
Operating incomeCurrentYTDDuration3055000000JPY
Interest income noiPrior1YTDDuration0JPY
Interest income noiCurrentYTDDuration2000000JPY
Dividends income noiPrior1YTDDuration185000000JPY
Dividends income noiCurrentYTDDuration187000000JPY
Other noiPrior1YTDDuration51000000JPY
Other noiCurrentYTDDuration34000000JPY
Non operating incomePrior1YTDDuration236000000JPY
Non operating incomeCurrentYTDDuration224000000JPY
Interest expenses noePrior1YTDDuration25000000JPY
Interest expenses noeCurrentYTDDuration21000000JPY
Expenses of inactive non current assets noePrior1YTDDuration27000000JPY
Expenses of inactive non current assets noeCurrentYTDDuration35000000JPY
Other noePrior1YTDDuration75000000JPY
Other noeCurrentYTDDuration127000000JPY
Non operating expensesPrior1YTDDuration128000000JPY
Non operating expensesCurrentYTDDuration183000000JPY
Ordinary incomePrior1YTDDuration2987000000JPY
Ordinary incomeCurrentYTDDuration3096000000JPY
Gain on sales of investment securities eiPrior1YTDDuration32000000JPY
Gain on sales of investment securities eiCurrentYTDDuration2314000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass